SCHEDULE 13G: Perceptive Advisors Discloses 9.99% Stake in Opus Genetics

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 9.99% beneficial ownership stake in Opus Genetics, Inc. through a Schedule 13G filing.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership of 4,510,501 shares of Common Stock in Opus Genetics, Inc.
• This ownership represents 9.99% of the Issuer's outstanding Common Stock.
• The calculation of the ownership percentage is based on an aggregate of 44,964,664 shares of Common Stock outstanding, as reported by Opus Genetics, Inc. in its Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on March 24, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds 4,325,000 shares of Common Stock.
• The Master Fund also holds Pre-Funded Warrants exercisable for 8,832,895 shares of Common Stock at an exercise price of $0.001 per share.
• Additionally, the Master Fund holds Common Warrants exercisable for 13,157,895 shares of Common Stock at an exercise price of $0.95 per share.
• Both types of Warrants are subject to a Beneficial Ownership Limitation, which prevents their exercise if it would result in the Reporting Persons beneficially owning more than 9.99% of the shares of Common Stock then issued and outstanding.
• As of the filing date, this limitation permits the Reporting Persons to exercise Warrants for up to 185,501 shares of Common Stock.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors, granting them shared voting and dispositive power over the shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a reputable life sciences investment firm like Perceptive Advisors is generally viewed positively by the market, indicating institutional confidence in the company. While a 13G is a factual filing, the nature of the investor and the size of the stake suggest a positive underlying sentiment.

Positives

• A significant beneficial ownership stake of 9.99% by a prominent investment firm like Perceptive Advisors, known for its focus on life sciences, signals confidence in Opus Genetics, Inc.'s prospects.
• The holding of both common stock and warrants indicates a strategic, long-term investment approach and potential for increased ownership if the beneficial ownership limitation allows.

Risks

• The Beneficial Ownership Limitation restricts the Reporting Persons from exercising all their warrants if it would result in ownership exceeding 9.99% of the outstanding shares, potentially limiting their ability to fully capitalize on their warrant holdings.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a specialized life sciences fund, Perceptive Advisors, in Opus Genetics, Inc., a company likely operating within the biotechnology or pharmaceutical sector. Such investments are common in the life sciences industry where specialized funds seek to capitalize on potential breakthroughs and growth in emerging companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a near-10% stake may instill greater confidence in existing and potential shareholders, potentially leading to increased investor interest and share price stability.
• Company Management: The investment by Perceptive Advisors could be seen as a validation of the company's strategy and prospects, potentially aiding future fundraising efforts or strategic partnerships.

Key Dates

Keywords

Opus Genetics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, institutional investment, biotechnology, life sciences